Tags: tivicay | dolutegravir | hiv | aids | fda

New HIV Medication

Thursday, 15 Aug 2013 05:25 PM

 

Share:
  Comment  |
   Contact Us  |
  Print  
|  A   A  
  Copy Shortlink
Tivicay (dolutegravir) has been approved by the U.S. Food and Drug Administration to treat infection with HIV-1, a strain of the virus that causes AIDS.

The drug, among a class called integrase strand transfer inhibitors, interferes with an enzyme that HIV needs to multiply. It's been approved in combination with other antiretroviral drugs and for people aged 12 and older who weigh at least 88 pounds, the FDA said in a news release.
 
Some 50,000 Americans acquire HIV infection each year, and about 15,500 people died from the disease in 2010, the agency said, citing the U.S. Centers for Disease Control and Prevention.
 
The drug's safety and effectiveness were evaluated in clinical studies involving more than 2,500 adults and children, the FDA said. The most common side effects included difficulty sleeping, headache and more serious problems including allergic-like reactions and abnormal liver function in people who had hepatitis B or C.
 
Tivicay is produced by GlaxoSmithKline, based in Research Triangle Park, N.C.

© HealthDay

Share:
  Comment  |
   Contact Us  |
  Print  
  Copy Shortlink
Around the Web
Comments
Please review Community Guidelines before posting a comment.
>> Register to share your comments with the community.
>> Login if you are already a member.
blog comments powered by Disqus
 
Email:
Retype Email:
Country
Zip Code:
Privacy: We never share your email.
 
Find Your Condition
You May Also Like
Around the Web
Most Commented

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, NewsmaxWorld, NewsmaxHealth, are trademarks of Newsmax Media, Inc.

NEWSMAXHEALTH.COM
© Newsmax Media, Inc.
All Rights Reserved